A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors

Nano Research

Volumn 8, Issue 5, 2015, Pages 1505-1521

  Shahbazi, Mohammad Ali ^a   Shrestha, Neha ^a   Mäkilä, Ermei ^a,b   Araújo, Francisca ^a,c,d   Correia, Alexandra ^a   Ramos, Tomás ^e   Sarmento, Bruno ^c,f   Salonen, Jarno ^b   Hirvonen, Jouni ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

antibody; breast cancer; CD326; chemo immunotherapy; drug targeting; porous silicon nanoparticles

Indexed keywords

EID: 84939635524     PISSN: 19980124     EISSN: 19980000     Source Type: Journal    
DOI: 10.1007/s12274-014-0635-4     Document Type: Article

References (52)

1. Nowak, A. K.; Lake, R. A.; Robinson, B. W. Combined chemoimmunotherapy of solid tumours: Improving vaccines. Adv. Drug Deliv. Rev.2006, 58, 975–990.
2. Lee, I. H.; An, S.; Yu, M. K.; Kwon, H. K.; Im, S. H.; Jon, S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release2011, 155, 435–441.
3. Molavi, O.; Xiong, X. B.; Douglas, D.; Kneteman, N.; Nagata, S.; Pastan, I.; Chu, Q.; Lavasanifar, A.; Lai, R. Anti-cd30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials2013, 34, 8718–8725.
4. Maeda, H.; Matsumura, Y. Epr effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv. Drug Deliv. Rev.2011, 63, 129–130.
5. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev.2008, 60, 1615–1626.
6. Chattopadhyay, N.; Fonge, H.; Cai, Z.; Scollard, D.; Lechtman, E.; Done, S. J.; Pignol, J. P.; Reilly, R. M. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol. Pharmaceutics2012, 9, 2168–2179.
7. Lu, Y. M.; Huang, J. Y.; Wang, H.; Lou, X. F.; Liao, M. H.; Hong, L. J.; Tao, R. R.; Ahmed, M. M.; Shan, C. L.; Wang, X. L. et al. Targeted therapy of brain ischaemia using Fas ligand antibody conjugated peg-lipid nanoparticles. Biomaterials2014, 35, 530–537.
8. Fiandra, L.; Mazzucchelli, S.; De Palma, C.; Colombo, M.; Allevi, R.; Sommaruga, S.; Clementi, E.; Bellini, M.; Prosperi, D.; Corsi, F. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. ACS Nano2013, 7, 6092–6102.
9. Weiner, L. M.; Surana, R.; Wang, S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol.2010, 10, 317–327.
10. Portnoy, E.; Lecht, S.; Lazarovici, P.; Danino, D.; Magdassi, S. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine2011, 7, 480–488.
11. Berlin, J. M.; Pham, T. T.; Sano, D.; Mohamedali, K. A.; Marcano, D. C.; Myers, J. N.; Tour, J. M. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery. ACS Nano2011, 5, 6643–6650.
12. Gu, L.; Ruff, L. E.; Qin, Z.; Corr, M.; Hedrick, S. M.; Sailor, M. J. Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic cd40 antibody. Adv. Mater.2012, 24, 3981–3987.
13. Illum, L.; Jones, P. D.; Baldwin, R. W.; Davis, S. S. Tissue distribution of poly(hexyl-2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J. Pharmacol. Exp. Ther.1984, 230, 733–736.
14. Chinol, M.; Casalini, P.; Maggiolo, M.; Canevari, S.; Omodeo, E. S.; Caliceti, P.; Veronese, F. M.; Cremonesi, M.; Chiolerio, F.; Nardone, E. et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br. J. Cancer1998, 78, 189–197.
15. Scott, D.; Nitecki, D. E.; Kindler, H.; Goodman, J. W. Immunogenicity of biotinylated hapten-avidin complexes. Mol. Immunol.1984, 21, 1055–1060.
16. Zhao, J.; Mi, Y.; Liu, Y.; Feng, S. S. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials2012, 33, 1948–1958.
17. Liu, Y.; Li, K.; Liu, B.; Feng, S. S. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials2010, 31, 9145–9155.
18. Venturelli, E.; Fabbro, C.; Chaloin, O.; Menard-Moyon, C.; Smulski, C. R.; Da Ros, T.; Kostarelos, K.; Prato, M.; Bianco, A. Antibody covalent immobilization on carbon nanotubes and assessment of antigen binding. Small2011, 7, 2179–2187.
19. Firer, M. A.; Gellerman, G. Targeted drug delivery for cancer therapy: The other side of antibodies. J. Hematol. Oncol.2012, 5, 70.
20. Mitra, M.; Misra, R.; Harilal, A.; Sahoo, S. K.; Krishnakumar, S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol. Vis.2011, 17, 2724–2737.
21. Winter, M. J.; Nagtegaal, I. D.; van Krieken, J. H.; Litvinov, S. V. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol.2003, 163, 2139–2148.
22. Martowicz, A.; Spizzo, G.; Gastl, G.; Untergasser, G. Phenotype-dependent effects of epcam expression on growth and invasion of human breast cancer cell lines. BMC Cancer2012, 12, 501.
23. Santos, H. A.; Bimbo, L. M.; Herranz, B.; Shahbazi, M. A.; Hirvonen, J.; Salonen, J. Nanostructured porous silicon in preclinical imaging: Moving from bench to bed side. J. Mater. Res.2013, 28, 152–164.
24. Shahbazi, M. A.; Almeida, P. V.; Mäkilä, E.; Correia, A.; Ferreira, M. P.; Kaasalainen, M.; Salonen, J.; Hirvonen, J.; Santos, H. A. Poly(methyl vinyl ether-alt-maleic acid)-functionalized porous silicon nanoparticles for enhanced stability and cellular internalization. Macromol. Rapid Commun.2014, 35, 624–629.
25. Shahbazi, M. A.; Hamidi, M.; Mäkilä, E. M.; Zhang, H.; Almeida, P. V.; Kaasalainen, M.; Salonen, J. J.; Hirvonen, J. T.; Santos, H. A. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials2013, 34, 7776–7789.
26. Shahbazi, M. A.; Herranz, B.; Santos, H. A. Nanostructured porous Si-based nanoparticles for targeted drug delivery. Biomatter2012, 2, 296–312.
27. Barnes, T. J.; Jarvis, K. L.; Prestidge, C. A. Recent advances in porous silicon technology for drug delivery. Ther. Deliv.2013, 4, 811–823.
28. Zhang, M.; Xu, R.; Xia, X.; Yang, Y.; Gu, J.; Qin, G.; Liu, X.; Ferrari, M.; Shen, H. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells. Biomaterials2014, 35, 423–431.
29. Tabasi, O.; Falamaki, C.; Khalaj, Z. Functionalized mesoporous silicon for targeted-drug-delivery. Colloids Surf. B-Biointerfaces2012, 98, 18–25.
30. Ferris, D. P.; Lu, J.; Gothard, C.; Yanes, R.; Thomas, C. R.; Olsen, J. C.; Stoddart, J. F.; Tamanoi, F.; Zink, J. I. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small2011, 7, 1816–1826.
31. Xu, R.; Huang, Y.; Mai, J.; Zhang, G.; Guo, X.; Xia, X.; Koay, E. J.; Qin, G.; Erm, D. R.; Li, Q. et al. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small2013, 9, 1799–1808.
32. Rytkönen, J.; Arukuusk, P.; Xu, W.; Kurrikoff, K.; Langel, U.; Lehto, V. P.; Närvänen, A. Porous silicon-cell penetrating peptide hybrid nanocarrier for intracellular delivery of oligonucleotides. Mol. Pharmaceutics2013, 11, 382–390.
33. Secret, E.; Smith, K.; Dubljevic, V.; Moore, E.; Macardle, P.; Delalat, B.; Rogers, M. L.; Johns, T. G.; Durand, J. O.; Cunin, F. et al. Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs. Adv. Health. Mater.2013, 2, 718–727.
34. Santos, H. A.; Riikonen, J.; Salonen, J.; Mäkilä, E.; Heikkilä, T.; Laaksonen, T.; Peltonen, L.; Lehto, V. P.; Hirvonen, J. In vitro cytotoxicity of porous silicon microparticles: Effect of the particle concentration, surface chemistry and size. Acta Biomater.2010, 6, 2721–2731.
35. Shrestha, N; Shahbazi, M. A; Araújo, F; Zhang, H; Mäkilä, E; Kauppila, J; Sarmento, B; Salonen, J; Hirvonen, J; Santos, H. A. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials2014, 35, 7172–7179.
36. Shahbazi, M. A.; Almeida, P. V.; Mäkilä, E.; Kaasalainen, N.; Salonen, J.; Hirvonen, J.; Santos, H. A. Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials2014, 35, 7488–7500.
37. Jalkanen, T.; Mäkilä, E.; Sakka, T.; Salonen, J.; Ogata, Y. H. Thermally promoted addition of undecylenic acid on thermally hydrocarbonized porous silicon optical reflectors. Nanoscale Res. Lett.2012, 7, 311.
38. Occhipinti, E.; Verderio, P.; Natalello, A.; Galbiati, E.; Colombo, M.; Mazzucchelli, S.; Salvade, A.; Tortora, P.; Doglia, S. M.; Prosperi, D. Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles. Nanoscale2011, 3, 387–390.
39. Danhier, F.; Feron, O.; Preat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release2010, 148, 135–146.
40. Sasidharan, S.; Jayasree, A.; Fazal, S.; Koyakutty, M.; Nair, S. V.; Menon, D. Ambient temperature synthesis of citrate stabilized and biofunctionalized, fluorescent calcium fluoride nanocrystals for targeted labeling of cancer cells. Biomater. Sci.2013, 1, 294–305.
41. Kong, J.; Yu, S. Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim. Biophys. Sin. (Shanghai)2007, 39, 549–559.
42. Kwon, I. K.; Lee, S. C.; Han, B.; Park, K. Analysis on the current status of targeted drug delivery to tumors. J. Control. Release2012, 164, 108–114.
43. Shen, J.; Sun, H.; Meng, Q.; Yin, Q.; Zhang, Z.; Yu, H.; Li, Y. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA. Mol. Pharmaceutics2014, 11, 3342–3351.
44. Seidel, U. J.; Schlegel, P.; Lang, P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front. Immunol.2013, 4, 76.
45. Weiner, L. M.; Dhodapkar, M. V.; Ferrone, S. Monoclonal antibodies for cancer immunotherapy. Lancet2009, 373, 1033–1040.
46. Chowdhury, F.; Lode, H. N.; Cragg, M. S.; Glennie, M. J.; Gray, J. C. Development of immunomonitoring of antibody-dependent cellular cytotoxicity against neuroblastoma cells using whole blood. Cancer Immunol. Immunother.2014, 63, 559–569.
47. Iannello, A.; Ahmad, A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev.2005, 24, 487–499.
48. van Sorge, N. M.; van der Pol, W. L.; van de Winkel, J. G. Fcgammar polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens2003, 61, 189–202.
49. Smith, K. A. Interleukin-2: Inception, impact, and implications. Science1988, 240, 1169–1176.
50. Strome, S. E.; Sausville, E. A.; Mann, D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist2007, 12, 1084–1095.
51. Kawaguchi, Y.; Kono, K.; Mimura, K.; Sugai, H.; Akaike, H.; Fujii, H. Cetuximab induce antibody-dependent cellular cytotoxicity against egfr-expressing esophageal squamous cell carcinoma. Int. J. Cancer2007, 120, 781–787.
52. El-Dakdouki, M. H.; Pure, E.; Huang, X. Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. Nanoscale2013, 5, 3895–3903.